Surgical strategy of non-small cell lung cancer with Ⅲa staging

doi:10.3760/cma.j.issn.1673-422X.2019.04.011

Abstract

Abstract: Patients with Ⅲa staging have a large proportion in non-small cell lung cancer (NSCLC). These patients often lost the opportunity to complete excision of the tumor because the tumor have invaded adjacent vital organs when diagnosed. Besides, Ⅲa staging contains a lot of complicated clinical TNM stages, so, the opinions of experts at home and abroad are various about treatment of NSCLC with Ⅲa staging. Neoadjuvant therapy, surgery, radiation therapy and chemotherapy play important roles under different conditions. Especially surgery is occupying a pivotal position in comprehensive therapy of Ⅲa NSCLC.

Key words: Carcinoma, non-small-cell lung, Surgical procedures, operative, Neoplasm staging

Zhao Qingchun, Zhang Zihe, Chen Jun. Surgical strategy of non-small cell lung cancer with Ⅲa staging[J]. Journal of International Oncology, 2019, 46(4): 243-247.

References

［1］ Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016［J］. CA Cancer J Clin, 2016, 66(4): 271-289. DOI: 10.3322/caac.21349. ［2］ Savic M, Kontic M, Ercegovac M, et al. Comparison of mediastinal lymph node status and relapse pattern in clinical stage ⅢA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: a single center experience［J］. Thorac Cancer, 2017, 8(5): 393-401. DOI: 10.1111/1759-7714.12447. ［3］ Wood DE, Kazerooni EA, Baum SL, et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology［J］. J Natl Compr Canc Netw, 2018, 16(4): 412-441. DOI: 10.6004/jnccn.2018.0020. ［4］ Naqos N, Belbaraka R, El Omrani A, et al. Non-small lung cancer, ECCO/ESMO congres 2017［J］. Rev Pneumol Clin, 2018, 74(2): 61-66. DOI: 10.1016/j.pneumo.2018.02.001. ［5］ Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage Ⅲ non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines［J］. Chest, 2013, 143(5 Suppl): e314S-e340S. DOI: 10.1378/chest.12-2360. ［6］ Feng W, Li Y, Shen L, et al. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage ⅢA(N2) non-small cell lung cancer［J］. Oncotarget, 2016, 7(6): 7227-7240. DOI: 10.18632/oncotarget.6979. ［7］ Shimodaira Y, Slack RS, Harada K, et al. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial［J］. Br J Cancer, 2018, 118(3): 331-337. DOI: 10.1038/bjc.2017.423. ［8］ McElnay P, Lim E. Adjuvant or neoadjuvant chemotherapy for NSCLC［J］. J Thorac Dis, 2014, 6(Suppl 2): S224-S227. DOI: 10.3978/j.issn.2072-1439.2014.04.26. ［9］ NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data［J］. Lancet, 2014, 383(9928): 1561-1571. DOI: 10.1016/S0140-6736(13)62159-5. ［10］ Tong S, Qin Z, Wan M, et al. Induction chemoradiotherapy versus induction chemotherapy for potentially resectable stage ⅢA (N2) non-small cell lung cancer: a systematic review and meta-analysis［J］. J Thorac Dis, 2018, 10(4): 2428-2436. DOI: 10.21037/jtd.2018.04.24. ［11］ Gonfiotti A, Viggiano D, Voltolini L, et al. Enhanced recovery after surgery and video-assisted thoracic surgery lobectomy: the Italian VATS Group surgical protocol［J］. J Thorac Dis, 2018, 10(Suppl 4): S564-S570. DOI: 10.21037/jtd.2018.01.157. ［12］ Bendixen M, Licht PB. Video-assisted thoracoscopic surgery versus open lobectomy for lung cancer: time for a randomized trial［J］. Eur J Cardiothorac Surg, 2017, 52(2): 398. DOI: 10.1093/ejcts/ezx078. ［13］ Falcoz PE, Puyraveau M, Thomas PA, et al. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database［J］. Eur J Cardiothorac Surg, 2016, 49(2): 602-609. DOI: 10.1093/ejcts/ezv154. ［14］ Laursen LØ, Petersen RH, Hansen HJ, et al. Video-assisted thoracoscopic surgery lobectomy for lung cancer is associated with a lower 30-day morbidity compared with lobectomy by thoracotomy［J］. Eur J Cardiothorac Surg, 2016, 49(3): 870-875. DOI: 10.1093/ejcts/ezv205. ［15］ Mafé JJ, Planelles B, Asensio S, et al. Cost and effectiveness of lung lobectomy by video-assisted thoracic surgery for lung cancer［J］. J Thorac Dis, 2017, 9(8): 2534-2543. DOI: 10.21037/jtd.2017.07.51. ［16］ Taioli E, Lee DS, Lesser M, et al. Long-term survival in video-assisted thoracoscopic lobectomy vs open lobectomy in lung-cancer patients: a meta-analysis［J］. Eur J Cardiothorac Surg, 2013, 44(4): 591-597. DOI: 10.1093/ejcts/ezt051. ［17］张文军, 解明然, 马冬春. 全胸腔镜肺癌手术研究进展［J］. 国际肿瘤学杂志, 2015, 42(11): 860-862. DOI: 10.3760/cma.j.issn.1673-422X.2015.11.017. ［18］ Merritt RE, Hoang CD, Shrager JB. Lymph node evaluation achieved by open lobectomy compared with thoracoscopic lobectomy for N0 lung cancer［J］. Ann Thorac Surg, 2013, 96(4): 1171-1177. DOI: 10.1016/j.athoracsur.2013.05.044. ［19］ Woodard GA, Jablons DM. The latest in surgical management of stage ⅢA non-small cell lung cancer: video-assisted thoracic surgery and tumor molecular profiling［C/OL］. Am Soc Clin Oncol Educ Book, 2015: e435-e441. DOI: 10.14694/EdBook_AM.2015.35.e435. ［20］ Novellis P, Bottoni E, Voulaz E, et al. Robotic surgery, video-assisted thoracic surgery, and open surgery for early stage lung cancer: comparison of costs and outcomes at a single institute［J］. J Thorac Dis, 2018, 10(2): 790-798. DOI: 10.21037/jtd.2018.01.123. ［21］ Egberts JH, Schlemminger M, Schafmayer C, et al. Robot-assisted minimally invasive lobectomy with systematic lymphadenectomy for lung cancer［J］. Zentralbl Chir, 2015, 140(1): 15-16. DOI: 10.1055/s-0034-1396253. ［22］ Veronesi G, Park B, Cerfolio R, et al. Robotic resection of Stage Ⅲ lung cancer: an international retrospective study［J］. Eur J Cardiothorac Surg, 2018, 54(5): 912-919. DOI: 10.1093/ejcts/ezy166. ［23］ Shrimali RK, Nallathambi C, Saha A, et al. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center［J］. Indian J Cancer, 2018, 55(2): 125-133. DOI: 10.4103/ijc.IJC_469_17. ［24］ Gagliasso M, Migliaretti G, Ardissone F. Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery［J］. Lung Cancer, 2017, 111: 124-130. DOI: 10.1016/j.lungcan.2017.07.013. ［25］ Reardon ES, Schrump DS. Extended resections of nonsmall cell lung cancers invading the aorta, pulmonary artery, left atrium, or esophagus: can they be justified［J］. Thorac Surg Clin, 2014, 24(4): 457-464. DOI: 10.1016/j.thorsurg.2014.07.012. ［26］ Van Schil PE, Hendriks JM, Lauwers P. Focus on treatment complications and optimal management surgery［J］. Transl Lung Cancer Res, 2014, 3(3): 181-186. DOI: 10.3978/j.issn.2218-6751.2014.06.07. ［27］张彦军, 王军, 张小龙, 等. 393例食管胃结合部腺癌淋巴结转移的特征及其影响因素［J］. 中华肿瘤杂志, 2016, 38(9): 672-676. DOI: 10.3760/cma.j.issn.0253-3766.2016.09.007. ［28］ Mokhles S, Macbeth F, Treasure T, et al. Systematic lymphadenectomy versus sampling of ipsilateral mediastinal lymphnodes during lobectomy for non-small-cell lung cancer: a systematic review of randomized trials and a meta-analysis［J］. Eur J Cardiothorac Surg, 2017, 51(6): 1149-1156. DOI: 10.1093/ejcts/ezw439. ［29］ Tantraworasin A, Saeteng S, Siwachat S, et al. Impact of lymph node management on resectable non-small cell lung cancer patients［J］. J Thorac Dis, 2017, 9(3): 666-674. DOI: 10.21037/jtd.2017.02.90. ［30］ Meng D, Zhou Z, Wang Y, et al. Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis［J］. Eur J Cardiothorac Surg, 2016, 50(4): 597-604. DOI: 10.1093/ejcts/ezw083. ［31］ Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) nonsmall cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial［J］. J Thorac Cardiovasc Surg, 2011, 141(3): 662-670. DOI: 10.1016/j.jtcvs.2010.11.008. ［32］ Huang X, Wang J, Chen Q, et al. Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review and metaanalysis［J］. PLoS One, 2014, 9(10): e109979. DOI: 10.1371/journal.pone.0109979. ［33］ Bille A, Woo KM, Ahmad U, et al. Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage Ⅰ lung cancer patients［J］. Eur J Cardiothorac Surg, 2017, 51(4): 674-679. DOI: 10.1093/ejcts/ezw400. ［34］ Wang S, Zhang B, Li C, et al. Prognostic value of number of negative lymph node in patients with stage Ⅱ and Ⅲa non-small cell lung cancer［J］. Oncotarget, 2017, 8(45): 79387-79396. DOI: 10.18632/oncotarget.18154. ［35］ Taylor MD, Lapar DJ, Thomas CJ, et al. Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer［J］. Ann Thorac Surg, 2013, 96(4): 1163-1170. DOI: 10.1016/j.athoracsur.2013.04.031. ［36］ Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM Classification for Lung Cancer［J］. J Thorac Oncol, 2015, 10(12): 1675-1684. DOI: 10.1097/JTO.0000000000000678.

[1]	Yuan Chenyang, Zhou Juying, Du Xiao, Ji Huan, Zhao Tianyi. Comparison of 2018 and 2009 FIGO staging system of cervical cancer and analysis of prognostic factors [J]. Journal of International Oncology, 2022, 49(3): 151-163.
[2]	Chen Fangming, Cai Yuanyuan, Li Han, Wang Xiaoli, Kan Hongxing, Li Yang, Hao Furong, Wang Mingchen. Prognostic differences of nasopharyngeal carcinoma patients treated with intensity-modulated radiothe-rapy with different T staging of the seventh and eighth edition of the UICC staging system [J]. Journal of International Oncology, 2021, 48(9): 515-522.
[3]	Zeng Manting1, Liu Jihua1, Zhou Ningbo2, Wang Jian1, Li Xuanxuan1, Zhu Hong1. Application of shear wave elastography in cervical cancer [J]. Journal of International Oncology, 2019, 46(2): 117-120.
[4]	Pan Xingxi, Chen Yongfa, Li Feilong, Liu Mindong, Tang Wu-bing, Yang Wen. Comparison analysis of local invasion between the Chinese 2017 staging system and the 2008 staging system for nasopharyngeal carcinoma [J]. Journal of International Oncology, 2018, 45(11): 652-656.
[5]	Lu Rongzeng, Liu Jianshan, Lei Xing, Gao Yongtao, Gao Hongyan, Bai Tiecheng. Applacation of imaging examination in the preoperative staging diagnosis of colorectal cancer [J]. Journal of International Oncology, 2017, 44(8): 622-625.
[6]	Teng Fei, Cui Guimin, Shi Hongyun, Liu Miaoling, Li Yanhong. Clinical observation of radiotherapy combined with temozolomide in non-small cell lung cancer patients with brain metastases [J]. Journal of International Oncology, 2017, 44(4): 271-273.
[7]	YIN Yun-Fei, ZHANG Tao. Application of high resolution magnetic resonance imaging in locally advanced rectal cancer [J]. Journal of International Oncology, 2017, 44(2): 151-154.
[8]	LI Jun-Ting, ZHANG Yin-Hua, ZHAO Feng. Relationships between androgen receptor expression and clinicopathological features and prognosis of earlyonset breast cancer in Xinjiang [J]. Journal of International Oncology, 2016, 43(8): 651-654.
[9]	Zhao Xinru, Zhao Yuye, Li Guohong, Kan Xuan, Niu Zuoxing. Research progress of immunoscore [J]. Journal of International Oncology, 2016, 43(10): 772-774.
[10]	Qian Wenchuan, Wang Fan. Preliminary study on the relationship between thrombocytosis and gastric cancer [J]. Journal of International Oncology, 2014, 41(5): 380-382.
[11]	TANG Shi-Min, LI Wen-Hui, CHANG Li. Significance of histologic molecular markers for prognosis of the ⅢA (N2) phase non-small cell lung cancer [J]. Journal of International Oncology, 2014, 41(3): 203-205.
[12]	Li Pang, Gao Jie, Li Sheng. Clinical application of circulating tumor cells detection [J]. Journal of International Oncology, 2014, 41(2): 99-102.
[13]	CAI Wen-Ke, SHI Yun-?. NSCLC staging system and the implication of 7th lung cancer TNM classification [J]. Journal of International Oncology, 2013, 40(7): 523-526.
[14]	QIN Qin, LI Bao-Sheng. MRI in the diagnosis and staging of lung cancer [J]. Journal of International Oncology, 2013, 40(10): 762-765.
[15]	LIU Zi-Feng, LI Gui-Xin. Cancer cachexia diagnosis and therapy [J]. Journal of International Oncology, 2012, 39(7): 510-513.